Actively Recruiting
Chinese Adults With Kidney Disease
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-05-01
30
Participants Needed
10
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
CONDITIONS
Official Title
Chinese Adults With Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Mean eGFR greater than or equal to 30 mL/min/1.73m2
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
You will not qualify if you...
- Previous kidney transplant or major solid organ transplant
- Required renal replacement therapy for more than 72 hours
- Rapidly progressive glomerular nephritis or acute kidney injury
- History of recurrent invasive infection
- Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan)
- Active TB, HIV or other systemic infection
- Abnormal liver function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
ADARx Clinical Site
Shenzhen, Guangdong, China, 518100
Actively Recruiting
2
ADARx Clinical Site
Guiyang, Guizhou, China
Actively Recruiting
3
ADARx Clinical Site
Zhengzhou, Henan, China
Not Yet Recruiting
4
ADARx Clinical Site
Baotou, Inner Mongolia, China, 014000
Actively Recruiting
5
ADARx Clinical Site
Wuxi, Jiangsu, China, 214000
Actively Recruiting
6
ADARx Clinical Site
Yantai, Shandong, China, 264008
Actively Recruiting
7
ADARx Clinical Site
Beijing, China, 100034
Actively Recruiting
8
ADARx Clinical Site
Shandong, China
Not Yet Recruiting
9
ADARx Clinical Site
Shanghai, China
Not Yet Recruiting
10
ADARx Clinical Site
Shangxi, China
Not Yet Recruiting
Research Team
S
Stephanie Leyva
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here